{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:22:43Z","timestamp":1781184163322,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"JSPS KAKENHI","award":["15K09157"],"award-info":[{"award-number":["15K09157"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0691-2","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T12:43:18Z","timestamp":1507639398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Circulating adipocyte fatty acid-binding protein is a predictor of cardiovascular events in patients with stable angina undergoing percutaneous coronary intervention"],"prefix":"10.1186","volume":"17","author":[{"given":"Wataru","family":"Takagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-3439","authenticated-orcid":false,"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nishibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hirohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"issue":"24","key":"691_CR1","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J AM Coll Cardiol. 2012;60(24):e44\u2013e164.","journal-title":"J AM Coll Cardiol"},{"issue":"9","key":"691_CR2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1311890","volume":"371","author":"S Yusuf","year":"2014","unstructured":"Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818\u201327.","journal-title":"N Engl J Med"},{"issue":"5291","key":"691_CR3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1126\/science.274.5291.1377","volume":"274","author":"GS Hotamisligil","year":"1996","unstructured":"Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274(5291):1377\u20139.","journal-title":"Science"},{"issue":"2","key":"691_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.1700930204","volume":"93","author":"C Gold","year":"1967","unstructured":"Gold C. A primary mesothelioma involving the rectovaginal septum and associated with beryllium. J Pathol Bacteriol. 1967;93(2):435\u201342.","journal-title":"J Pathol Bacteriol"},{"issue":"10","key":"691_CR5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1161\/01.ATV.0000033090.81345.E6","volume":"22","author":"JB Boord","year":"2002","unstructured":"Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22(10):1686\u201391.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"691_CR6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/89076","volume":"7","author":"L Makowski","year":"2001","unstructured":"Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001;7(6):699\u2013705.","journal-title":"Nat Med"},{"issue":"4","key":"691_CR7","doi-asserted-by":"crossref","first-page":"e19115","DOI":"10.1371\/journal.pone.0019115","volume":"6","author":"Y Bao","year":"2011","unstructured":"Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, et al. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PLoS One. 2011;6(4):e19115.","journal-title":"PLoS One"},{"key":"691_CR8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1475-2840-10-44","volume":"10","author":"M Doi","year":"2011","unstructured":"Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, et al. Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 2011;10:44.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"691_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/EJE-08-0665","volume":"160","author":"EJ Rhee","year":"2009","unstructured":"Rhee EJ, Lee WY, Park CY, KW O, Kim BJ, Sung KC, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009;160(2):165\u201372.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"691_CR10","doi-asserted-by":"crossref","first-page":"e27356","DOI":"10.1371\/journal.pone.0027356","volume":"6","author":"M Furuhashi","year":"2011","unstructured":"Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011;6(11):e27356.","journal-title":"PLoS One"},{"issue":"9","key":"691_CR11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1161\/ATVBAHA.112.248609","volume":"32","author":"M von Eynatten","year":"2012","unstructured":"von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012;32(9):2327\u201335.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"691_CR12","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/ATVBAHA.115.305365","volume":"35","author":"H Reiser","year":"2015","unstructured":"Reiser H, Klingenberg R, Hof D, Cooksley-Decasper S, Fuchs N, Akhmedov A, et al. Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arterioscler Thromb Vasc Biol. 2015;35(8):1872\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"691_CR13","doi-asserted-by":"crossref","first-page":"e004176","DOI":"10.1161\/JAHA.112.004176","volume":"2","author":"WS Chow","year":"2013","unstructured":"Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J Am Heart Assoc. 2013;2(1):e004176.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"691_CR14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.atherosclerosis.2010.01.032","volume":"211","author":"T Miyoshi","year":"2010","unstructured":"Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, et al. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010;211(1):164\u20139.","journal-title":"Atherosclerosis"},{"key":"691_CR15","doi-asserted-by":"crossref","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A et al.: 2014 ACC\/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation 2015, 132(4):302\u2013361.","DOI":"10.1161\/CIR.0000000000000156"},{"issue":"16","key":"691_CR16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020\u201335.","journal-title":"Circulation"},{"issue":"3","key":"691_CR17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa0807611","volume":"360","author":"PA Tonino","year":"2009","unstructured":"Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Van\u2019t Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213\u201324.","journal-title":"N Engl J Med"},{"issue":"10","key":"691_CR18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s001250100643","volume":"44","author":"RM Fisher","year":"2001","unstructured":"Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001;44(10):1268\u201373.","journal-title":"Diabetologia"},{"issue":"2","key":"691_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00404-014-3422-2","volume":"291","author":"M Doganay","year":"2015","unstructured":"Doganay M, Ozyer SS, Var T, Tonguc E, Gun Eryilmaz O, Ozer I, et al. Associations between adipocyte fatty acid-binding protein and clinical parameters in polycystic ovary syndrome. Arch Gynecol Obstet. 2015;291(2):447\u201350.","journal-title":"Arch Gynecol Obstet"},{"key":"691_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1475-2840-11-72","volume":"11","author":"G Aragones","year":"2012","unstructured":"Aragones G, Saavedra P, Heras M, Cabre A, Girona J, Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol. 2012;11:72.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"691_CR21","doi-asserted-by":"crossref","first-page":"e81914","DOI":"10.1371\/journal.pone.0081914","volume":"8","author":"J Girona","year":"2013","unstructured":"Girona J, Rosales R, Plana N, Saavedra P, Masana L, Vallve JC. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One. 2013;8(11):e81914.","journal-title":"PLoS One"},{"issue":"5","key":"691_CR22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/ATVBAHA.116.307225","volume":"36","author":"M Furuhashi","year":"2016","unstructured":"Furuhashi M, Fuseya T, Murata M, Hoshina K, Ishimura S, Mita T, et al. Local Production of Fatty Acid-Binding Protein 4 in Epicardial\/Perivascular Fat and Macrophages Is Linked to Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):825\u201334.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"691_CR23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00380-010-0060-x","volume":"26","author":"T Miyoshi","year":"2011","unstructured":"Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessel. 2011;26(4):408\u201313.","journal-title":"Heart Vessel"},{"issue":"6","key":"691_CR24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00380-012-0310-1","volume":"28","author":"M Kajiya","year":"2013","unstructured":"Kajiya M, Miyoshi T, Doi M, Usui S, Iwamoto M, Takeda K, et al. Serum adipocyte fatty acid-binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease. Heart Vessel. 2013;28(6):696\u2013703.","journal-title":"Heart Vessel"},{"key":"691_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-11-26","volume":"11","author":"M Iwamoto","year":"2012","unstructured":"Iwamoto M, Miyoshi T, Doi M, Takeda K, Kajiya M, Nosaka K, et al. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc Diabetol. 2012;11:26.","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"691_CR26","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1073\/pnas.0602178103","volume":"103","author":"G Tuncman","year":"2006","unstructured":"Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci U S A. 2006;103(18):6970\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"691_CR27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12944-016-0177-8","volume":"15","author":"M Furuhashi","year":"2016","unstructured":"Furuhashi M, Hiramitsu S, Mita T, Omori A, Fuseya T, Ishimura S, et al. Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. Lipids Health Dis. 2016;15:5.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"691_CR28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2362.2007.01835.x","volume":"37","author":"M Karpisek","year":"2007","unstructured":"Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Investig. 2007;37(8):637\u201342.","journal-title":"Eur J Clin Investig"},{"issue":"12","key":"691_CR29","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1194\/jlr.M059469","volume":"56","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi M, Hiramitsu S, Mita T, Fuseya T, Ishimura S, Omori A, et al. Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus. J Lipid Res. 2015;56(12):2372\u201380.","journal-title":"J Lipid Res"},{"issue":"4","key":"691_CR30","doi-asserted-by":"crossref","first-page":"e0154482","DOI":"10.1371\/journal.pone.0154482","volume":"11","author":"M Furuhashi","year":"2016","unstructured":"Furuhashi M, Matsumoto M, Hiramitsu S, Omori A, Tanaka M, Moniwa N, et al. Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor. PLoS One. 2016;11(4):e0154482.","journal-title":"PLoS One"},{"issue":"7147","key":"691_CR31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature05844","volume":"447","author":"M Furuhashi","year":"2007","unstructured":"Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447(7147):959\u201365.","journal-title":"Nature"},{"issue":"2","key":"691_CR32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/cn5002107","volume":"6","author":"Y Wang","year":"2015","unstructured":"Wang Y, Lin HQ, Law WK, Liang WC, Zhang JF, Hu JS, et al. Pimozide, a novel fatty acid binding protein 4 inhibitor, promotes adipogenesis of 3T3-L1 cells by activating PPARgamma. ACS Chem Neurosci. 2015;6(2):211\u20138.","journal-title":"ACS Chem Neurosci"},{"key":"691_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2014.11.020","volume":"90","author":"H Cai","year":"2015","unstructured":"Cai H, Liu Q, Gao D, Wang T, Chen T, Yan G, et al. Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination. Eur J Med Chem. 2015;90:241\u201350.","journal-title":"Eur J Med Chem"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:23:50Z","timestamp":1659590630000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0691-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0691-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]},"article-number":"258"}}